Recent developments include a reported drop in Q3 profit in October 2025, multiple insider buying reports in 2025, and trading halts and resumptions in late 2024. The company is exploring strategic alternatives and a potential spinoff of its Celle subsidiary, currently on hold due to the Duke License Agreement dispute.

• Cryo-Cell International reported a drop in Q3 profit as of October 2025 [N1].
• Insider buying activity was reported multiple times in 2025, including September and August [N2][N3].
• Trading of Cryo-Cell International shares was halted and then resumed in October 2024 due to volatility trading pause [N6][N5].
• The company announced plans to explore strategic alternatives and a potential spinoff of its Celle subsidiary, though this is on hold pending resolution of the Duke License Agreement dispute [N8].

Cryo-Cell’s established leadership as the first private cord blood bank and its extensive specimen inventory provide a strong foundation for continued service to families and public banking clients. The company’s advanced processing technology and accredited facilities support high-quality outcomes and client trust. Expansion into third-party cold storage services through ExtraVault offers diversification opportunities. Insider buying activity reported in 2025 may indicate confidence from management or insiders. The company’s marketing focus on increasing awareness could enhance market penetration over time. The financial snapshot shows profitability and positive earnings per share as of August 2026, supporting operational viability.

The termination of the Duke License Agreement in 2025 has paused Cryo-Cell’s planned expansion into infusion clinics and biopharmaceutical manufacturing, limiting growth avenues. The proposed spinoff of Celle Corp. is on hold pending resolution of the Duke dispute, creating strategic uncertainty. Liquidity ratios below 1 as of August 2026 indicate potential short-term financial constraints. The cord blood preservation market faces challenges including low market penetration due to cost perceptions and lack of awareness. Increased competition from public cord blood banks and regulatory complexities may pressure margins. Recent news of profit declines and trading halts highlight operational and market risks. The company’s reliance on evolving medical technology and regulatory approvals adds uncertainty.

Cryo-Cell International benefits from its status as the world's first private cord blood bank with over 30 years of operational history and a large global inventory of over 250,000 stored specimens. Its facilities hold cGMP and cGTP compliance along with AABB and FACT accreditations, underscoring high-quality standards. The company’s proprietary PrepaCyte® CB Processing System and a 100% viability rate of specimens upon thaw provide technological differentiation. Its payment warranty program offers client assurance. The acquisition of Cord:Use assets expanded its public cord blood inventory, enhancing market reach. The company’s infrastructure, including a large storage facility with third-party service capabilities, supports scalability. These factors collectively create barriers to entry and competitive advantages in the cord blood banking and storage market.

• Duke License Agreement Termination: The termination of the Duke License Agreement in May 2025 has halted Cryo-Cell’s expansion into infusion clinics and biopharmaceutical manufacturing, with no assurance of resumption or successful resolution of the dispute.
• Liquidity and Financial Constraints: As of August 31, 2026, the company’s current ratio is 0.86 and cash ratio is 0.28, indicating potential short-term liquidity challenges that could impact operations or investments.
• Market Penetration and Competition: The cord blood preservation market has low penetration due to cost misperceptions and lack of awareness. Increased competition from public cord blood banks, especially internationally, may affect revenue and growth.
• Regulatory and Operational Risks: The company faces risks from government regulation of stem cell storage facilities, potential facility failures, and compliance with FDA and other regulatory requirements, which could impact operations and reputation.
• Strategic Uncertainty: The proposed spinoff of Celle Corp. is on hold and may not occur depending on the outcome of the Duke dispute, creating uncertainty around strategic initiatives and resource allocation.

• Cryo-Cell International, Inc. is a Delaware corporation incorporated in 1989 and was the world's first private cord blood bank to separate and store stem cells in 1992 [S1].
• The company operates three reportable segments: (1) cellular processing and cryogenic storage for family use focusing on umbilical cord blood and tissue stem cells, (2) manufacture of PrepaCyte® CB Processing System units used to process umbilical cord blood stem cells, and (3) cellular processing and cryogenic storage of umbilical cord blood stem cells for public use [S1].
• Cryo-Cell and its global affiliates currently store over 250,000 cord blood and cord tissue specimens worldwide for the exclusive benefit of newborns and possibly their families [S1].
• The company’s U.S.-based operations, including processing and storage, are headquartered in Oldsmar, Florida, with specimens primarily stored in a technologically advanced facility in Durham, North Carolina [S1].
• Cryo-Cell offers cord tissue storage services introduced in 2011, storing a section of the umbilical cord tissue which is a rich source of mesenchymal stromal cells (MSCs) with potential regenerative properties [S1].
• The company entered into a Patent and Technology License Agreement with Duke University in 2021 to develop expanded business units including infusion clinic services and biopharmaceutical manufacturing, but Duke terminated the agreement effective May 17, 2025, and the company has paused related investments and the planned Cryo-Cell Institute for Cellular Therapies [S1].
• Cryo-Cell acquired assets of Cord:Use Cord Blood Bank in 2018, creating a large, ethnically diverse public cord blood inventory stored in North Carolina and distributed through the National Marrow Donor Program [S1].
• The company purchased a 56,000 square-foot facility in Durham, NC, to support storage needs and offer third-party cold storage services (ExtraVault) to biopharmaceutical companies and medical institutions [S1].
• Cryo-Cell’s facility is cGMP- and cGTP-compliant with AABB and FACT accreditation, and the company claims a 100% viability rate of specimens upon thaw for therapeutic use since inception [S1].
• The company offers a payment warranty up to $100,000 for clients if the cord blood product fails to engraft in a transplant under certain conditions [S1].
• Marketing efforts focus on educating expectant parents and prenatal care providers about the medical benefits of stem cell preservation, addressing low market penetration due to cost misperceptions and lack of awareness [S1].
• Financial snapshot as of August 31, 2026, includes cash and equivalents of $1.43 million, short-term investments of $2.8 million, current assets of $13.17 million, current liabilities of $15.33 million, resulting in a current ratio of 0.86 and a cash ratio of 0.28 [S2].
• For the quarter ended August 31, 2026, the company reported net income of approximately $1.27 million and basic and diluted EPS of $0.16 [S2].
• Recent news highlights include a reported drop in Q3 profit in October 2025, insider buying activity reported multiple times in 2025, and a trading halt and resumption in October 2024 [N1][N2][N3][N5][N6].
• The company is exploring strategic alternatives and the potential spinoff of its Celle subsidiary, though this is on hold pending resolution of the Duke License Agreement dispute [N8][S1].